Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 5/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | THPO | P40225 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.51 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15733793 | 0.82 | GRM5 (0.59) | GRM5NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL30123501 | 0.82 | GRM5 (0.59) | GRM5NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL15733106 | 0.75 | PDE10A (0.71) | GRM5NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL15733249 | 0.75 | PDE10A (0.67) | GRM5NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL23087698 | 0.71 | NPC1 (0.41) | NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL24494372 | 0.71 | GRM5 (0.76) | GRM5NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL15734051 | 0.71 | GRM5 (0.56) | GRM5NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL3562130 | 0.70 | HTR2A (0.47) | NPC1RAB9ASMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL103061 | 0.70 | GRM5 (1.00) | GRM5NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL29355216 | 0.70 | GRM5 (1.00) | GRM5NPC1RAB9ASMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180030033-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2018-02-01 | — | — | US | disclosed |
| US-9790203-B2 | Inhibitor compounds of phosphodiesterase type 10A | ABBVIE INC. (US) | 2017-10-17 | — | — | US | disclosed |
| EP-2922842-B1 | INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | ABBVIE INC (US) | 2017-06-14 | — | — | EP | disclosed |
| EP-2922842-A2 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | AbbVie Inc. (US) | 2015-09-30 | — | — | EP | disclosed |
| WO-2014079995-A2 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | ABBVIE INC. (US) | 2014-05-30 | — | — | WO | disclosed |
| US-20140148461-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180030033-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | PDE1A, PDE1B, PDE3A | GRM5 2399/4885NPC1 2521/4885RAB9A 659/4885 |
| US-20140148461-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | PDE1A, PDE1B, PDE3A | GRM5 2464/4885NPC1 2513/4885RAB9A 658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.